Latest Breaking News On - Atara biotherapeutics inc - Page 7 : vimarsana.com

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...

Atara Biotherapeutics (NASDAQ:ATRA) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock. ATRA has been the subject of a number of other reports. Mizuho cut shares of Atara Biotherapeutics from a buy rating to a neutral […]

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of AAR Corp. (NYSE:AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported...

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session - AAR (NYSE:AIR), Advent Technologies Hldgs (NASDAQ:ADN)

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $28.00 Average Price Target from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have been assigned a consensus rating of “Hold” from the four brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average […]

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or...

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T BenchmarkNo Observed Treatment-Related Toxicities or AlloreactivityData Supports Advancement Into IND-Enabling StudiesTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeu...

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate in...